https://scholars.lib.ntu.edu.tw/handle/123456789/631868
Title: | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis | Authors: | Sunami, Kazutaka Ikeda, Takashi SHANG-YI HUANG Wang, Ming-Chung Koh, Youngil Min, Chang Ki Yeh, Su-Peng Matsumoto, Morio Uchiyama, Michihiro Iyama, Satoshi Shimazaki, Chihiro Lee, Jae Hoon Kim, Kihyun Kaneko, Hitomi Kim, Jin Seok Lin, Tung-Liang Campana, Frank Tada, Keisuke Iida, Shinsuke Suzuki, Kenshi |
Keywords: | Efficacy and safety; Far East; Isa-Pd; Japan; RRMM | Issue Date: | Aug-2022 | Publisher: | CIG MEDIA GROUP, LP | Journal Volume: | 22 | Journal Issue: | 8 | Start page/Pages: | E751 | Source: | Clinical lymphoma, myeloma & leukemia | Abstract: | In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/631868 | ISSN: | 2152-2650 | DOI: | 10.1016/j.clml.2022.04.005 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.